Peanut Allergy

PEANUT
Molecular Allergology
Precise results for

safe decisions
How to better identify and manage peanut allergy
Take the diagnosis and management
of peanut allergic patients to a whole new level
Better risk assessment with allergen components
• How can you differentiate between “true” peanut allergy or symptoms caused by cross-reactivity?
• Is there a risk of severe reaction for the patient?

• How can you best manage their peanut allergy?
Better differentiation of the peanut allergic patient

• The presence of Specific IgE to Ara h 1, Ara h 2 and Ara h 3 is indicative of a “true” peanut allergy
and a high risk of severe reactions 1–3
• Sensitization to the cross-reactive allergen components Ara h 8 and Ara h 9 (present in pollen and
plant foods) varies depending on local exposure 4–6
• Sensitization to several peanut allergen components indicates increased risk for severe reactions 1–3
Better patient management

• Evaluate your patients’ risk of severe reactions to peanut
• Ensure relevant dietary advice and avoid unnecessary elimination

• Define the optimal treatment for your patients
Proper diagnosis of patients with

suspected peanut allergy improves
quality of life
Results that reveal more
Recommended test profile:

Peanut (f 13) and Ara h 1 and Ara h 2 and Ara h 3 and Ara h 9* and Ara h 8*
results:
Peanut (f 13) + Ara h 1 / Ara h 2 / Ara h 3 + Ara h 9* + Ara h 8*
+ + + –
Risk for severe
reactions to
peanut
Risk for reactions

+ – + + to peanut due to
cross reactivity
* According to local exposure
All peanut components are needed

for a complete risk assessment and
indication of severe reactions
Did you know that?

• In children, approximately 10 % are considered peanut sensitized 7 but only 1–2 % are “true”
peanut allergic. 8–10 Ara h 2 is the most important peanut allergen component but antibodies to
Ara h 1 and/or Ara h 3 in addition increases the risk of severe reactions 1–3, 7
• Patients with “true” peanut allergy often have antibodies to Ara h 2. However, in rare cases
sensitization to only Ara h 1 and/or Ara h 3 can occur 11
• IgE antibodies to the Ara h 8 are seldom associated with systemic reactions but more often to
local reactions like OAS (oral allergy syndrome 4,12
• The amount of Ara h 9 in a peanut is low and severe reactions in peanut allergy are not so
well documented. However, sensitization to LTP (Lipid transfer protein) is generally associated
with severe reactions in addition to OAS 5,6
Make a precise assessment
ImmunoCAP Allergen Components help you differentiate between ”true” allergies
and cross-reactivity
Make a substantiated decision

A better differentiation helps you give relevant advice and define the optimal treatment
Make a difference
More informed management helps you improve the patient’s well-being and quality of life
References: 1. Astier C. et al. J Allergy Clin Immunol 2006; 118: 250–256. 2. Flinterman AE. et al. Clin Exp Allergy 2007; 37(8): 1221–1228. 3. Peeters KABM et al. Clin Exp
Allergy 2007; 37(1): 108–115. 4. Mittag D et al. J Allergy Clin Immunol 2004; 114: 1410–1417. 5. Lauer I. et al. Clin Exp Allergy 2009; 39 1427–1437. 6. Krause S. et al. J Allergy
Clin Immunol 2009; 124: 771–778. 7. Nicolaou N et al. J Allergy Clin Immunol 2010; 125: 191–197. 8. Mortz CG et al. Pediatr Allergy Immunol 2005; 16:501–506. 9. Tariq et al.
BMJ 1996; 313(7056): 514–517. 10. Moneret-Vautrin DA et al. Allergy 2005;60:443–451. 11. Codreanu et al. Int.Arch.Allergy.Immunol 2011; 154: 216–226 (Epub ahead of print).
12. Asarnoj A. et al. Allergy 2010; 65: 1189–1195.
thermoscientific.com/phadia
© 2013 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific Inc. and its subsidiaries.
Manufacturer; Phadia AB, Uppsala Sweden.
Head office Sweden +46 18 16 50 00 Germany +49 761 47 8050 Spain +34 935 765 800
Austria +43 1 270 20 20 Hong Kong +852 2885 4613 Sweden +46 18 16 60 60
Belgium +32 2 749 55 15 India +91 11 4610 7555/56 Switzerland +41 43 343 4050
Brazil + 55 11 3345 5050 Italy +39 02 64 163 411 Taiwan +886 2 2516 0925
China +86 21 6865 4588 Japan +81 3 5365 8332 The Netherlands +31 30 602 37 00
Czech Republic +420 220 518 743 Korea +82 2 2027 5400 United Kingdom/Ireland +44 1 908 769 110
Denmark +45 70 23 33 06 Norway +47 21 67 32 80 USA +1 800 346 4364
Finland +358 9 3291 0110 Portugal +351 21 423 5350 Other countries +46 18 16 50 00
France +33 1 61 37 34 30 South Africa +27 11 792 6790
52-5108-59/05 928-2300 1301 heart.se

Peanut Allergy

Uploaded by

Copyright:

Available Formats

Peanut Allergy

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Peanut Allergy

Uploaded by

Copyright:

Available Formats

PEANUT

Precise results for

• Is there a risk of severe reaction for the patient?

Better differentiation of the peanut allergic patient

Better patient management

• Ensure relevant dietary advice and avoid unnecessary elimination

Proper diagnosis of patients with

Recommended test profile:

Risk for reactions

All peanut components are needed

Did you know that?

Make a substantiated decision

52-5108-59/05 928-2300 1301 heart.se

You might also like